[CAS NO. 2649776-79-2] MPH-220
PRODUCTS SPECIFICATIONS [2649776-79-2]
DESCRIPTION [2649776-79-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 383.46 |
| Molecular Formula | C20H21N3O3S |
| SMILES | O[C@@]12C(N(C3=CC=C(N4CCOCC4)C=C3)CC2)=NC5=C(C=C(S5)C)C1=O |
Summary
MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2 . MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness [1] .
In Vitro
MPH-220 (0-50 µM) inhibits Actin-activated ATPase activity in human muscle myosin samples
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MPH-220 (25-30 mg/kg, i.p. or oral gavage) reduces skeletal muscle force without cardiovascular effects in anesthetized rats
[1]
.
MPH-220 (15 mg/kg, oral administration) improves gait functions in rats with brain injury
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Anesthetized rats [1] |
| Dosage: | 25-30 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) or oral gavage |
| Result: |
Reduced skeletal muscle force.
Observed MPH-220 distribution in rat tissues in a time-dependent manner and a dose-dependent, few-fold accumulation in skeletal muscle. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.